---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-22-000030"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2022-03-31T23:59:59+00:00"
generated_at: "2026-06-26T12:30:24.792108+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotechnology appoints Karen Akinsanya, Schrödinger President, to Board

## Summary
- Appointment effective March 30, 2022; Akinsanya will serve as Class III director through 2024.
- Akinsanya is President of R&D, Therapeutics at Schrödinger and has 25+ years in drug discovery.
- Director compensation: $40,000/year plus initial option award of 105,998 shares ($370K grant date FV).
- She joins a board that includes leaders from genomics, cancer therapeutics, and tech (Illumina, Perceptive Advisors, etc.).

## SEC filing metadata
- accession: 0001808805-22-000030
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2022-03-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000030/0001808805-22-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000030/naut-20220330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-22-000030
- JSON: https://secwatch.observer/filing/0001808805-22-000030.json
- Plain text: https://secwatch.observer/filing/0001808805-22-000030.txt

## Key facts
- Executive change
  Karen Akinsanya was appointed as Director at Nautilus Biotechnology, Inc..
  - Action: appointed
  - Role: Director
  source text: On March 30, 2022 , the board of directors (the “Board”) of Nautilus Biotechnology, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, appointed Karen Akinsanya to the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880522000030/0001808805-22-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.